1. Home
  2. INBS vs LABT Comparison

INBS vs LABT Comparison

Compare INBS & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$1.79

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$1.85

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INBS
LABT
Founded
2016
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
4.6M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
INBS
LABT
Price
$1.79
$1.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
36.0K
253.1K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
68.65
N/A
EPS
N/A
N/A
Revenue
$1,980,484.00
N/A
Revenue This Year
$778.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.66
52 Week High
$24.90
$4.72

Technical Indicators

Market Signals
Indicator
INBS
LABT
Relative Strength Index (RSI) 28.84 26.54
Support Level $0.59 $1.88
Resistance Level $2.46 $2.92
Average True Range (ATR) 0.17 0.43
MACD -0.02 -0.09
Stochastic Oscillator 23.21 12.50

Price Performance

Historical Comparison
INBS
LABT

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Share on Social Networks: